;PMID: 8647319 ;source_file_1899.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..45] = [t:0..45] ;1)sentence:[e:51..133] = [t:51..133] ;2)section:[e:137..173] = [t:137..173] ;3)section:[e:177..245] = [t:177..245] ;4)sentence:[e:249..456] = [t:249..456] ;5)sentence:[e:457..733] = [t:457..733] ;6)sentence:[e:734..915] = [t:734..915] ;7)sentence:[e:916..1252] = [t:916..1252] ;8)sentence:[e:1254..1617] = [t:1254..1617] ;9)sentence:[e:1618..1777] = [t:1618..1777] ;10)sentence:[e:1778..1916] = [t:1778..1916] ;11)sentence:[e:1917..2259] = [t:1917..2259] ;12)section:[e:2263..2307] = [t:2263..2307] ;section 0 Span:0..45 ;Mol Cell Endocrinol. 1996 Feb 5;116(2):191-8. (SEC (FRAG (NNP:[0..3] Mol) (NNP:[4..8] Cell) (NNP:[9..19] Endocrinol) (.:[19..20] .) (CD:[21..25] 1996) (NNP:[26..29] Feb) (CD:[30..36] 5;116-LRB-) (CD:[36..37] 2) (-RRB-:[37..38] -RRB-) (CD:[38..43] :191-) (CD:[43..45] 8.))) ;sentence 1 Span:51..133 ;Differential effects of oxytocin on steroid production by bovine granulosa ;cells. ;[75..83]:substance:"oxytocin" ;[87..94]:substance:"steroid" (SENT (NP-HLN (NP (JJ:[51..63] Differential) (NNS:[64..71] effects)) (PP (IN:[72..74] of) (NP (NN:[75..83] oxytocin))) (PP (IN:[84..86] on) (NP (NP (NN:[87..94] steroid) (NN:[95..105] production)) (PP (IN:[106..108] by) (NP (JJ:[109..115] bovine) (NN:[116..125] granulosa) (NNS:[127..132] cells))))) (.:[132..133] .))) ;section 2 Span:137..173 ;Berndtson AK, Weaver CJ, Fortune JE. (SEC (FRAG (NNP:[137..146] Berndtson) (NNP:[147..149] AK) (,:[149..150] ,) (NNP:[151..157] Weaver) (NNP:[158..160] CJ) (,:[160..161] ,) (NNP:[162..169] Fortune) (NNP:[170..173] JE.))) ;section 3 Span:177..245 ;Department of Physiology, Cornell University, Ithaca, NY 14853, USA. (SEC (FRAG (NNP:[177..187] Department) (IN:[188..190] of) (NNP:[191..201] Physiology) (,:[201..202] ,) (NNP:[203..210] Cornell) (NNP:[211..221] University) (,:[221..222] ,) (NNP:[223..229] Ithaca) (,:[229..230] ,) (NNP:[231..233] NY) (CD:[234..239] 14853) (,:[239..240] ,) (NNP:[241..244] USA) (.:[244..245] .))) ;sentence 4 Span:249..456 ;Oxytocin (OT) and its mRNA are expressed at very low levels in granulosa ;cells from bovine preovulatory follicles isolated before the LH/FSH surge ;and increase dramatically between the surge and ovulation. ;[249..257]:substance:"Oxytocin" ;[259..261]:substance:"OT" ;[271..275]:substance:"mRNA" ;[384..386]:substance:"LH" ;[387..390]:substance:"FSH" (SENT (S (NP-SBJ-1 (NP (NP (NN:[249..257] Oxytocin)) (NP (-LRB-:[258..259] -LRB-) (NN:[259..261] OT) (-RRB-:[261..262] -RRB-))) (CC:[263..266] and) (NP (PRP$:[267..270] its) (NN:[271..275] mRNA))) (VP (VP (VBP:[276..279] are) (VP (VBN:[280..289] expressed) (NP-1 (-NONE-:[289..289] *)) (PP (IN:[290..292] at) (NP (ADJP (RB:[293..297] very) (JJ:[298..301] low)) (NNS:[302..308] levels))) (PP-LOC (IN:[309..311] in) (NP (NP (NN:[312..321] granulosa) (NNS:[322..327] cells)) (PP (IN:[329..333] from) (NP (NP (JJ:[334..340] bovine) (JJ:[341..353] preovulatory) (NNS:[354..363] follicles)) (VP (VBN:[364..372] isolated) (NP (-NONE-:[372..372] *)) (PP-TMP (IN:[373..379] before) (NP (DT:[380..383] the) (NML (NN:[384..386] LH) (SYM:[386..387] /) (NN:[387..390] FSH)) (NN:[391..396] surge)))))))))) (CC:[397..400] and) (VP (VBP:[401..409] increase) (ADVP (RB:[411..423] dramatically)) (PP-TMP (IN:[424..431] between) (NP (NP (DT:[432..435] the) (NN:[436..441] surge)) (CC:[442..445] and) (NP (NN:[446..455] ovulation)))))) (.:[455..456] .))) ;sentence 5 Span:457..733 ;We have shown previously that OT stimulates progesterone secretion by ;granulosa cells obtained before, but not after the gonadotropin surge, ;suggesting that OT may be involved in the follicular/luteal phase shift in ;steroidogenesis from estradiol/androgen to progesterone. ;[487..489]:substance:"OT" ;[502..514]:substance:"progesterone" ;[580..592]:substance:"gonadotropin" ;[616..618]:substance:"OT" ;[697..706]:substance:"estradiol" ;[707..715]:substance:"androgen" ;[720..732]:substance:"progesterone" (SENT (S (NP-SBJ (PRP:[457..459] We)) (VP (VBP:[460..464] have) (VP (VBN:[465..470] shown) (ADVP-TMP (RB:[471..481] previously)) (SBAR (IN:[482..486] that) (S (NP-SBJ (NN:[487..489] OT)) (VP (VBZ:[491..501] stimulates) (NP (NP (NN:[502..514] progesterone) (NN:[515..524] secretion)) (PP (IN:[525..527] by) (NP (NP (NN:[528..537] granulosa) (NNS:[538..543] cells)) (VP (VBN:[544..552] obtained) (NP (-NONE-:[552..552] *)) (PP-TMP (PP (IN:[553..559] before) (NP-2 (-NONE-:[559..559] *RNR*))) (,:[559..560] ,) (CONJP (CC:[561..564] but) (RB:[565..568] not)) (PP (IN:[570..575] after) (NP-2 (-NONE-:[575..575] *RNR*))) (NP-2 (DT:[576..579] the) (NN:[580..592] gonadotropin) (NN:[593..598] surge))))))) (,:[598..599] ,) (VP (VBG:[600..610] suggesting) (SBAR (IN:[611..615] that) (S (NP-SBJ-1 (NN:[616..618] OT)) (VP (MD:[619..622] may) (VP (VB:[623..625] be) (VP (VBN:[626..634] involved) (NP-1 (-NONE-:[634..634] *)) (PP-CLR (IN:[635..637] in) (NP (NP (DT:[638..641] the) (ADJP (JJ:[643..653] follicular) (SYM:[653..654] /) (JJ:[654..660] luteal)) (NN:[661..666] phase) (NN:[667..672] shift)) (PP (IN:[673..675] in) (NP (NN:[676..691] steroidogenesis))) (PP (IN:[692..696] from) (NP (NN:[697..706] estradiol) (SYM:[706..707] /) (NN:[707..715] androgen))) (PP (TO:[716..718] to) (NP (NN:[720..732] progesterone)))))))))))))))) (.:[732..733] .))) ;sentence 6 Span:734..915 ;One objective of this study was to determine if OT affects estradiol as well ;as progesterone production by utilizing culture conditions that maintain ;estradiol secretion in vitro. ;[782..784]:substance:"OT" ;[794..803]:substance:"estradiol" ;[815..827]:substance:"progesterone" ;[886..895]:substance:"estradiol" (SENT (S (NP-SBJ-3 (NP (CD:[734..737] One) (NN:[738..747] objective)) (PP (IN:[748..750] of) (NP (DT:[751..755] this) (NN:[756..761] study)))) (VP (VBD:[762..765] was) (S-PRP-PRD (NP-SBJ-3 (-NONE-:[765..765] *)) (VP (TO:[766..768] to) (VP (VB:[769..778] determine) (SBAR-ADV (IN:[779..781] if) (S (NP-SBJ (NN:[782..784] OT)) (VP (VBZ:[785..792] affects) (NP (NP (NN:[794..803] estradiol)) (CONJP (RB:[804..806] as) (RB:[807..811] well) (IN:[812..814] as)) (NP (NN:[815..827] progesterone) (NN:[828..838] production)))))) (PP-MNR (IN:[839..841] by) (S-NOM (NP-SBJ (-NONE-:[841..841] *)) (VP (VBG:[842..851] utilizing) (NP (NP (NN:[852..859] culture) (NNS:[860..870] conditions)) (SBAR (WHNP-1 (WDT:[872..876] that)) (S (NP-SBJ-1 (-NONE-:[876..876] *T*)) (VP (VBP:[877..885] maintain) (NP (NN:[886..895] estradiol) (NN:[896..905] secretion)) (ADVP-LOC (FW:[906..908] in) (FW:[909..914] vitro))))))))))))) (.:[914..915] .))) ;sentence 7 Span:916..1252 ;A second objective was to determine if OT regulates steroidogenesis by ;effects on the levels of mRNA for the steroidogenic enzymes involved in ;progesterone synthesis, cytochrome P450 side-chain cleavage (P450scc) and 3 ;beta-hydroxysteroid dehydrogenase (3 beta-HSD), or in estradiol production, ;cytochrome P450 aromatase (P450arom). ;[956..958]:substance:"OT" ;[1013..1017]:substance:"mRNA" ;[1041..1048]:substance:"enzymes" ;[1061..1073]:substance:"progesterone" ;[1085..1121]:cyp450:"cytochrome P450 side-chain cleavage" ;[1123..1130]:cyp450:"P450scc" ;[1136..1171]:substance:"3 beta-hydroxysteroid dehydrogenase" ;[1173..1184]:substance:"3 beta-HSD" ;[1193..1202]:substance:"estradiol" ;[1215..1240]:cyp450:"cytochrome P450 aromatase" ;[1242..1250]:cyp450:"P450arom" (SENT (S (NP-SBJ (DT:[916..917] A) (JJ:[918..924] second) (NN:[925..934] objective)) (VP (VBD:[935..938] was) (S-PRP-PRD (NP-SBJ (-NONE-:[938..938] *)) (VP (TO:[939..941] to) (VP (VB:[942..951] determine) (SBAR-ADV (IN:[953..955] if) (S (NP-SBJ (NN:[956..958] OT)) (VP (VBZ:[959..968] regulates) (NP (NN:[969..984] steroidogenesis)) (PP-MNR (IN:[985..987] by) (NP (NP (NNS:[988..995] effects)) (PP (IN:[996..998] on) (NP (NP (DT:[999..1002] the) (NNS:[1003..1009] levels)) (PP (IN:[1010..1012] of) (NP (NN:[1013..1017] mRNA))))))) (PP (IN:[1018..1021] for) (NP (NP (DT:[1022..1025] the) (JJ:[1027..1040] steroidogenic) (NNS:[1041..1048] enzymes)) (VP (VBN:[1049..1057] involved) (NP (-NONE-:[1057..1057] *)) (PP-CLR (PP (IN:[1058..1060] in) (NP (NP (NN:[1061..1073] progesterone) (NN:[1074..1083] synthesis)) (,:[1083..1084] ,) (NP (NP (NP (NML (NN:[1085..1095] cytochrome) (NN:[1096..1100] P450)) (NML (NN:[1102..1106] side) (HYPH:[1106..1107] -) (NN:[1107..1112] chain)) (NN:[1113..1121] cleavage)) (NP (-LRB-:[1122..1123] -LRB-) (NN:[1123..1130] P450scc) (-RRB-:[1130..1131] -RRB-))) (CC:[1132..1135] and) (NP (NP (CD:[1136..1137] 3) (NN:[1138..1157] beta-hydroxysteroid) (NN:[1158..1171] dehydrogenase)) (NP (-LRB-:[1172..1173] -LRB-) (CD:[1173..1174] 3) (NN:[1176..1184] beta-HSD) (-RRB-:[1184..1185] -RRB-)))))) (,:[1185..1186] ,) (CC:[1187..1189] or) (PP (IN:[1190..1192] in) (NP (NP (NN:[1193..1202] estradiol) (NN:[1203..1213] production)) (,:[1213..1214] ,) (NP (NP (NML (NN:[1215..1225] cytochrome) (NN:[1226..1230] P450)) (NN:[1231..1240] aromatase)) (NP (-LRB-:[1241..1242] -LRB-) (NN:[1242..1250] P450arom) (-RRB-:[1250..1251] -RRB-)))))))))))))))) (.:[1251..1252] .))) ;sentence 8 Span:1254..1617 ;Granulosa cells were isolated from bovine preovulatory follicles and cultured ; for 3 days with or without OT in medium supplemented with either insulin (1 ;microgram/ml) + 1% fetal calf serum (FCS), which maintains basal estradiol ;secretion, or low doses of FSH (1 and 2 ng/ml) + 1% FCS, a culture condition ;that maximizes effects of FSH on estradiol secretion. ;[1337..1338]:quantitative-value:"3" ;[1339..1343]:quantitative-units:"days" ;[1360..1362]:substance:"OT" ;[1398..1405]:substance:"insulin" ;[1407..1408]:quantitative-value:"1" ;[1410..1422]:quantitative-units:"microgram/ml" ;[1426..1428]:quantitative-value:"1%" ;[1475..1484]:substance:"estradiol" ;[1513..1516]:substance:"FSH" ;[1518..1519]:quantitative-value:"1" ;[1524..1525]:quantitative-value:"2" ;[1526..1531]:quantitative-units:"ng/ml" ;[1535..1537]:quantitative-value:"1%" ;[1590..1593]:substance:"FSH" ;[1597..1606]:substance:"estradiol" (SENT (S (NP-SBJ-4 (NN:[1254..1263] Granulosa) (NNS:[1264..1269] cells)) (VP (VBD:[1270..1274] were) (VP (VP (VBN:[1275..1283] isolated) (NP-4 (-NONE-:[1283..1283] *)) (PP (IN:[1284..1288] from) (NP (JJ:[1289..1295] bovine) (JJ:[1296..1308] preovulatory) (NNS:[1309..1318] follicles)))) (CC:[1319..1322] and) (VP (VBN:[1323..1331] cultured) (NP-4 (-NONE-:[1331..1331] *)) (PP-TMP (IN:[1333..1336] for) (NP (CD:[1337..1338] 3) (NNS:[1339..1343] days))) (PP-MNR (IN:[1344..1348] with) (CC:[1349..1351] or) (IN:[1352..1359] without) (NP (NN:[1360..1362] OT))) (PP-LOC (IN:[1363..1365] in) (NP (NP (NN:[1366..1372] medium)) (VP (VBN:[1373..1385] supplemented) (NP (-NONE-:[1385..1385] *)) (PP-MNR (IN:[1386..1390] with) (NP (CC:[1391..1397] either) (NP (NP (NP (NP (NN:[1398..1405] insulin)) (PRN (-LRB-:[1406..1407] -LRB-) (NP (NP (CD:[1407..1408] 1) (NN:[1410..1419] microgram)) (PP (SYM:[1419..1420] /) (NP (NN:[1420..1422] ml)))) (-RRB-:[1422..1423] -RRB-))) (PP (SYM:[1424..1425] +) (NP (NML (CD:[1426..1427] 1) (NN:[1427..1428] %)) (NML (NML (JJ:[1429..1434] fetal) (NN:[1435..1439] calf) (NN:[1440..1445] serum)) (NML (-LRB-:[1446..1447] -LRB-) (NN:[1447..1450] FCS) (-RRB-:[1450..1451] -RRB-)))))) (,:[1451..1452] ,) (SBAR (WHNP-3 (WDT:[1453..1458] which)) (S (NP-SBJ-3 (-NONE-:[1458..1458] *T*)) (VP (VBZ:[1459..1468] maintains) (NP (JJ:[1469..1474] basal) (NN:[1475..1484] estradiol) (NN:[1486..1495] secretion)))))) (,:[1495..1496] ,) (CC:[1497..1499] or) (NP (NP (NP (NP (JJ:[1500..1503] low) (NNS:[1504..1509] doses)) (PP (IN:[1510..1512] of) (NP (NN:[1513..1516] FSH))) (PRN (-LRB-:[1517..1518] -LRB-) (NP (NP (NP (CD:[1518..1519] 1) (NML-2 (-NONE-:[1519..1519] *P*))) (CC:[1520..1523] and) (NP (CD:[1524..1525] 2) (NML-2 (NN:[1526..1528] ng)))) (PP (SYM:[1528..1529] /) (NP (NN:[1529..1531] ml)))) (-RRB-:[1531..1532] -RRB-))) (PP (SYM:[1533..1534] +) (NP (NML (CD:[1535..1536] 1) (NN:[1536..1537] %)) (NN:[1538..1541] FCS)))) (,:[1541..1542] ,) (NP (NP (DT:[1543..1544] a) (NN:[1545..1552] culture) (NN:[1553..1562] condition)) (SBAR (WHNP-1 (WDT:[1564..1568] that)) (S (NP-SBJ-1 (-NONE-:[1568..1568] *T*)) (VP (VBZ:[1569..1578] maximizes) (NP (NP (NNS:[1579..1586] effects)) (PP (IN:[1587..1589] of) (NP (NN:[1590..1593] FSH))) (PP (IN:[1594..1596] on) (NP (NN:[1597..1606] estradiol) (NN:[1607..1616] secretion))))))))))))))))) (.:[1616..1617] .))) ;sentence 9 Span:1618..1777 ;After the first day of culture, OT stimulated progesterone (P < 0.01) and ;inhibited estradiol production (P < 0.01) in both control and FSH-treated ;cultures. ;[1651..1653]:substance:"OT" ;[1665..1677]:substance:"progesterone" ;[1703..1712]:substance:"estradiol" ;[1756..1759]:substance:"FSH" (SENT (S (PP-TMP (IN:[1618..1623] After) (NP (NP (DT:[1624..1627] the) (JJ:[1628..1633] first) (NN:[1634..1637] day)) (PP (IN:[1638..1640] of) (NP (NN:[1642..1649] culture))))) (,:[1649..1650] ,) (NP-SBJ (NN:[1651..1653] OT)) (VP (VP (VBD:[1654..1664] stimulated) (NP (NN:[1665..1677] progesterone)) (PRN (-LRB-:[1678..1679] -LRB-) (S (NP-SBJ (NN:[1679..1680] P)) (VP (SYM:[1681..1682] <) (NP (CD:[1683..1687] 0.01)))) (-RRB-:[1687..1688] -RRB-))) (CC:[1689..1692] and) (VP (VBD:[1693..1702] inhibited) (NP (NN:[1703..1712] estradiol) (NN:[1714..1724] production) (PRN (-LRB-:[1725..1726] -LRB-) (S (NP-SBJ (NN:[1726..1727] P)) (VP (SYM:[1728..1729] <) (NP (CD:[1730..1734] 0.01)))) (-RRB-:[1734..1735] -RRB-)))) (PP-LOC (IN:[1736..1738] in) (NP (CC:[1739..1743] both) (NP (NN:[1744..1751] control) (NML-1 (-NONE-:[1751..1751] *P*))) (CC:[1752..1755] and) (NP (ADJP (NN:[1756..1759] FSH) (HYPH:[1759..1760] -) (VBN:[1760..1767] treated)) (NML-1 (NNS:[1768..1776] cultures)))))) (.:[1776..1777] .))) ;sentence 10 Span:1778..1916 ;In contrast, OT had only a small stimulatory effect on the levels of mRNA ;for P450scc and 3 beta-HSD and no effect on mRNA for P450arom. ;[1791..1793]:substance:"OT" ;[1848..1852]:substance:"mRNA" ;[1857..1864]:cyp450:"P450scc" ;[1869..1880]:substance:"3 beta-HSD" ;[1898..1902]:substance:"mRNA" ;[1907..1915]:cyp450:"P450arom" (SENT (S (PP (IN:[1778..1780] In) (NP (NN:[1781..1789] contrast))) (,:[1789..1790] ,) (NP-SBJ (NN:[1791..1793] OT)) (VP (VBD:[1795..1798] had) (NP (NP (NP (RB:[1799..1803] only) (DT:[1804..1805] a) (JJ:[1806..1811] small) (JJ:[1812..1823] stimulatory) (NN:[1824..1830] effect)) (PP (IN:[1831..1833] on) (NP (NP (DT:[1834..1837] the) (NNS:[1838..1844] levels)) (PP (IN:[1845..1847] of) (NP (NN:[1848..1852] mRNA))))) (PP (IN:[1853..1856] for) (NP (NP (NN:[1857..1864] P450scc)) (CC:[1865..1868] and) (NP (CD:[1869..1870] 3) (NN:[1872..1880] beta-HSD))))) (CC:[1881..1884] and) (NP (NP (DT:[1885..1887] no) (NN:[1888..1894] effect)) (PP (IN:[1895..1897] on) (NP (NN:[1898..1902] mRNA))) (PP (IN:[1903..1906] for) (NP (NN:[1907..1915] P450arom)))))) (.:[1915..1916] .))) ;sentence 11 Span:1917..2259 ;These findings suggest that: (1) OT plays an autocrine role in regulating ;the follicular luteal phase shift in steroidogenesis by both increasing ;progesterone and inhibiting estradiol production and (2) the differential ;effects of OT on steroid production are not mediated primarily by effects on ;levels of mRNA for steroidogenic enzymes. ;[1950..1952]:substance:"OT" ;[2065..2077]:substance:"progesterone" ;[2093..2102]:substance:"estradiol" ;[2151..2153]:substance:"OT" ;[2157..2164]:substance:"steroid" ;[2228..2232]:substance:"mRNA" ;[2251..2258]:substance:"enzymes" (SENT (S (NP-SBJ (DT:[1917..1922] These) (NNS:[1923..1931] findings)) (VP (VBP:[1932..1939] suggest) (SBAR (IN:[1940..1944] that) (::[1944..1945] :) (S (S (LST (LS:[1946..1949] -LRB-1-RRB-)) (NP-SBJ-2 (NN:[1950..1952] OT)) (VP (VBZ:[1954..1959] plays) (NP (DT:[1960..1962] an) (JJ:[1963..1972] autocrine) (NN:[1973..1977] role)) (PP (IN:[1978..1980] in) (S-NOM (NP-SBJ-2 (-NONE-:[1980..1980] *)) (VP (VBG:[1981..1991] regulating) (NP (DT:[1992..1995] the) (JJ:[1996..2006] follicular) (JJ:[2007..2013] luteal) (NN:[2014..2019] phase) (NN:[2020..2025] shift)) (PP (IN:[2026..2028] in) (NP (NN:[2030..2045] steroidogenesis)))))) (PP-MNR (IN:[2046..2048] by) (S-NOM (NP-SBJ (-NONE-:[2048..2048] *)) (VP (CC:[2049..2053] both) (VP (VBG:[2054..2064] increasing) (NP (NN:[2065..2077] progesterone))) (CC:[2078..2081] and) (VP (VBG:[2082..2092] inhibiting) (NP (NN:[2093..2102] estradiol) (NN:[2104..2114] production)))))))) (CC:[2115..2118] and) (S (LST (LS:[2119..2122] -LRB-2-RRB-)) (NP-SBJ-1 (NP (DT:[2123..2126] the) (JJ:[2127..2139] differential) (NNS:[2140..2147] effects)) (PP (IN:[2148..2150] of) (NP (NN:[2151..2153] OT))) (PP (IN:[2154..2156] on) (NP (NN:[2157..2164] steroid) (NN:[2165..2175] production)))) (VP (VBP:[2176..2179] are) (RB:[2180..2183] not) (VP (VBN:[2185..2193] mediated) (NP-1 (-NONE-:[2193..2193] *)) (ADVP (RB:[2194..2203] primarily)) (PP (IN:[2204..2206] by) (NP-LGS (NP (NNS:[2207..2214] effects)) (PP (IN:[2215..2217] on) (NP (NP (NNS:[2218..2224] levels)) (PP (IN:[2225..2227] of) (NP (NN:[2228..2232] mRNA))))))) (PP (IN:[2233..2236] for) (NP (JJ:[2237..2250] steroidogenic) (NNS:[2251..2258] enzymes))))))))) (.:[2258..2259] .))) ;section 12 Span:2263..2307 ;PMID: 8647319 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2263..2267] PMID) (::[2267..2268] :) (CD:[2269..2276] 8647319) (-LRB-:[2277..2278] -LSB-) (NNP:[2278..2284] PubMed) (HYPH:[2285..2286] -) (NN:[2287..2294] indexed) (IN:[2295..2298] for) (NNP:[2299..2306] MEDLINE) (-RRB-:[2306..2307] -RSB-)))